MARAVAI LIFESCIENCES Reports Third Quarter Earnings Results for Fiscal Year 2023
December 4, 2023
🌥️Earnings Overview
On November 7, 2023, MARAVAI LIFESCIENCES ($NASDAQ:MRVI) announced their earnings results for the 3rd quarter of fiscal year 2023. Total revenue for the period ending September 30, 2023 was USD 66.9 million, a 65.0% decrease year-over-year. Net income for the quarter was reported to be USD -6.5 million, a drastic drop compared to the prior year’s figure of 44.5 million.
Market Price
The stock opened at $6.8 and closed at $6.9, up by 0.6% from the previous closing price of 6.8. This surge in the value of MARAVAI LIFESCIENCES shares demonstrates the company’s strong financial performance as they continue to grow and expand. The third quarter earnings report was met with positive sentiment on Wall Street, as investors are optimistic about the future of MARAVAI LIFESCIENCES. The company’s commitment to innovation and growth has allowed them to remain competitive in the sciences industry and remain a leader in their field.
Overall, the strong performance of MARAVAI LIFESCIENCES stocks demonstrates the company’s solid financial position and ability to continue to innovate and grow in the coming years. It is expected that the company will continue to have strong financial performance in the future as they continue to expand their reach and increase their value for shareholders. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Maravai Lifesciences. More…
| Total Revenues | Net Income | Net Margin |
| 419.52 | 24.56 | 7.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Maravai Lifesciences. More…
| Operations | Investing | Financing |
| 217.77 | -127.93 | -127.68 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Maravai Lifesciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.27k | 1.38k | 3.94 |
Key Ratios Snapshot
Some of the financial key ratios for Maravai Lifesciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 23.7% | 6.1% | 23.4% |
| FCF Margin | ROE | ROA |
| 38.8% | 11.8% | 2.7% |
Analysis
At GoodWhale, we take a look at MARAVAI LIFESCIENCES‘s fundamentals to help investors make informed decisions. According to our Star Chart, MARAVAI LIFESCIENCES is classified as a ‘rhino’, suggesting that the company has achieved moderate revenue or earnings growth. As such, investors who are looking for companies with steady, moderate growth may be interested in MARAVAI LIFESCIENCES. Additionally, our analysis shows that MARAVAI LIFESCIENCES has a high health score of 7/10, indicating that it is capable to sustain future operations in times of crisis. We consider that MARAVAI LIFESCIENCES is strong in growth, medium in asset, profitability and weak in dividend. All of these factors are important considerations for investors seeking to invest in such companies. More…
Peers
The competition between Maravai LifeSciences Holdings Inc and its competitors is fierce. Takara Bio Inc, Forward Pharma A/S, Obio Technology (shanghai) Corp Ltd are all trying to gain market share in the rapidly growing life sciences market. Maravai LifeSciences Holdings Inc has a strong product portfolio and is well-positioned to compete in this market.
– Takara Bio Inc ($TSE:4974)
Takara Bio Inc. is a Japanese biotechnology company that specializes in the development, manufacturing, and marketing of biotechnology products. The company was founded in 1953 and is headquartered in Kyoto, Japan. Takara Bio has four main business segments: biopharmaceuticals, bio-agriculture, bio-industry, and diagnostics. The company’s products include enzymes, proteins, antibodies, and nucleic acids used in research and development, drug discovery, and diagnostic applications. Takara Bio also offers agricultural products, such as plant growth regulators and soil amendments. In addition, the company provides contract research and development services.
– Forward Pharma A/S ($NASDAQ:FWP)
Write a paragraph on it’s market cap and ROE and a brief intro of what the company does:
Forward Pharma A/S has a market cap of 22.41M as of 2022, a Return on Equity of -3.32%. The Company is focused on developing and commercializing therapies for the treatment of inflammatory diseases.
– Obio Technology (shanghai) Corp Ltd ($SHSE:688238)
Obio Technology (shanghai) Corp Ltd is a publicly traded company with a market cap of 11.59B as of 2022. The company has a return on equity of 2.0%. The company is engaged in the business of providing technology solutions to businesses and consumers. The company’s products and services include software, hardware, and services. The company’s customers include businesses of all sizes, government entities, and individual consumers.
Summary
MARAVAI LIFESCIENCES reported an overall 65% decrease in revenue in the third quarter of 2023 compared to the same quarter in the previous year. This decrease was accompanied by a substantial drop in net income, which went from 44.5 million to -6.5 million. As a result, investors should be cautious when evaluating MARAVAI LIFESCIENCES for potential investments.
It is important to look at the company’s current financial performance, including its income, expenses, and cash flow, before investing. Furthermore, investors should research the company’s competitive landscape and determine if there is potential for long-term growth.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
